Sumio Iwanami

Aphoenix, Inc. is a holding company that operates as a chemical genomics firm. It specializes in the affinity purification technology using special nano-scale beads and other supporting technologies, such as medicinal chemistry, mass spectroscopy, informatics and molecular, biology. The firm exploits drugs, which lack known mechanisms of action as probes for discovering druggable targets, and then develop such compounds against validated targets. The company was founded in 2002 and is headquartered in Tokyo, Japan .

Aphoenix, Inc. is a holding company that operates as a chemical genomics firm. It specializes in the affinity purification technology using special nano-scale beads and other supporting technologies, such as medicinal chemistry, mass spectroscopy, informatics and molecular, biology. The firm exploits drugs, which lack known mechanisms of action as probes for discovering druggable targets, and then develop such compounds against validated targets. The company was founded in 2002 and is headquartered in Tokyo, Japan .

Aphoenix, Inc. is a holding company that operates as a chemical genomics firm. It specializes in the affinity purification technology using special nano-scale beads and other supporting technologies, such as medicinal chemistry, mass spectroscopy, informatics and molecular, biology. The firm exploits drugs, which lack known mechanisms of action as probes for discovering druggable targets, and then develop such compounds against validated targets. The company was founded in 2002 and is headquartered in Tokyo, Japan .